Heterocyclic Compounds

Matches 1 - 50 out of 54,490	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/155112A1	2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Novel 2,4-Dianilinopyrimidine-based Aurora-A kinase (AURKA) degraders are disclosed. The present AURKA degraders are proteolysis targeting chimeras (PROTACs) that recruit AURKA protein into optimized CRBN E3 ubiquitin ligase via linkers....
WO/2024/153217A1	INHIBITORS OF KIF18A AND USES THEREOF Described herein are KIF18A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with KIF18A.
WO/2024/153017A1	HETEROCYCLIC SUBSTITUTED PYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF The present disclosure relates to a heterocyclic substituted pyrazine compound, a preparation method therefor, and use thereof. Specifically, provided are a class of compounds represented by formula (I) or pharmaceutically acceptable sal...
WO/2024/153857A1	A METHOD FOR CRYSTALLIZATION OF ACTIVE PHARMACEUTICAL INGREDIENTS The disclosure relates to methods for crystallization of active pharmaceutical ingredients (APIs), wherein the crystallization and crystal growth is controlled According to the method solid amorphous nanosized API and an aqueous solution...
WO/2024/153112A1	PDE4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE The present disclosure relates to a PDE4 inhibitor, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a compound as represented by general formula (I), a preparation method...
WO/2024/153246A1	SUBSTITUTED TRICYCLIC COMPOUND AND USE THEREOF Provided are a compound of formula (I) which acts as a Cbl-b inhibitor, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition comprising the compound of formu...
WO/2024/153237A1	IGF-1R TYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND USE THEREOF The present disclosure relates to compounds represented by formula I, and pharmaceutically acceptable salts, isotope-labeled substances or isomers thereof, which are IGF-1R kinase inhibitors and can be used for treating diseases such as ...
WO/2024/155555A1	NEUROPROTECTIVE COMPOUNDS FOR THERAPEUTIC USE Provided are compounds that can reduce CD45+ CD4+ IFNy+ cells and inhibit or reduce inflammation. Also provided are methods of treating diseases characterized by inflammation using the compounds.
WO/2024/153143A1	NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF Provided in the present disclosure are a nitrogen-containing fused ring compound as represented by formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition containing same, and the use the...
WO/2024/153724A1	NOVEL PYRIMIDINYL SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and R6 are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/155717A1	METHODS AND COMPOSITIONS FOR TARGETING PD-L1 The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
WO/2024/153775A1	PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS The present invention relates to compounds of formula (I), (I) or pharmaceutically acceptable salts and/or solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined in the claims, which are useful as inhibitors of...
WO/2024/153945A1	INHIBITORS OF MPTP The invention relates to compounds of formula (I), and related aspects.
WO/2024/153105A1	FIVE-MEMBERED HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Disclosed in the present invention are a five-membered heterocyclic compound and a pharmaceutical composition thereof and the use thereof. The structure of the five-membered heterocyclic compound is as shown in formula (I). A stereoisome...
WO/2024/153946A1	INHIBITORS OF MPTP The invention relates to compounds of formula (I), and related aspects.
WO/2024/155618A1	COMPOSITIONS AND METHODS FOR TREATING WEIGHT GAIN AND/OR DISORDERS ASSOCIATED WITH ABNORMAL DE NOVO LIPOGENESIS, AND FAT ACCUMULATION A method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity in a subject in need thereof includes administering to the subject a therapeutically effective amount of a therapeutically e...
WO/2024/155864A1	SPRK1 INHIBITORS AND METHODS OF USE Provided herein are compounds having a structure of Formula (I) and pharmaceutically acceptable salts thereof which can act as modulators of serine/arginine-rich splicing factor protein kinase- 1 (SRPK1). Further disclosed herein are met...
WO/2024/153952A1	COMPOUNDS FOR NUCLEIC ACID CLEAVAGE The present invention relates to novel compounds of formula (I) defined herein that are suitable for the non-enzymatic cleavage of target nucleic acids. The present invention also relates to the pharmaceutical compositions comprising the...
WO/2024/153226A1	PYRAZOLE-FUSED CYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF The present disclosure relates to a compound represented by formula I, and a pharmaceutically acceptable salt, isotopic marker or isomer thereof. The compound is an IGF-1R kinase inhibitor and can be used for treating diseases such as th...
WO/2024/153247A1	COMPOUND AS CTPS1 INHIBITOR Provided in the present invention is a class of compounds. Specifically, provided in the present invention is a compound having a structure as shown in formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deutera...
WO/2024/153219A1	PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR The present disclosure relates to a pharmaceutically acceptable salt and a crystal form of a triazole compound, and a preparation method therefor. Specifically, provided in the present disclosure are a pharmaceutically acceptable salt an...
WO/2024/153063A1	CRYSTAL FORM OF ENPATORAN, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a new crystal form of Enpatoran (hereinafter referred to as "compound I"), and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in t...
WO/2024/152986A1	HETEROARYL AMINO COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF The present invention relates to a heteroaryl amino compound, a preparation method therefor, and use thereof, as well as a compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a deuterate...
WO/2024/153107A1	COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE The present invention provides a deuterated compound and a use thereof, and an organic electroluminescent device. The compound has a structure as shown in a formula (I), and is connected to a triazine structure by means of a specific fus...
WO/2024/152710A1	GLUTAMINYL CYCLASE INHIBITOR AND USE THEREOF A compound having a structure represented by formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug of the compound, wherein the connection relationship thereof is B-A-D-C. The compound is a glutaminyl cycla...
WO/2024/153947A1	INHIBITOR COMPOUNDS The present invention relates to compounds of Formula (I) that target MLH1, a component of the DNA Mismatch Repair (MMR) process: wherein R2, R3, R4, R5, Y1, Y2, A1, A2, A3, and A4 are each as defined herein. The present invention also r...
WO/2024/152973A1	PRMT5-MTA INHIBITOR Provided in the present invention is a compound as a PRMT5-MTA inhibitor, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Further provide...
WO/2024/152743A1	QUINOLINE DERIVATIVE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are quinoline derivative compounds or pharmaceutically acceptable salts thereof, a preparation method therefor, and the use thereof. The structural formula of the quinoline derivative compounds provided...
WO/2024/153067A1	HETEROCYCLE-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION, USE, AND PREPARATION METHOD THEREFOR Disclosed is a heterocycle-substituted five- and six-membered heteroaryl derivative, the structure of which is shown in formula (I). In addition, also disclosed are a pharmaceutically acceptable salt of the derivative, a stereoisomer the...
WO/2024/153950A1	COMPOUNDS FOR NUCLEIC ACID CLEAVAGE The present invention relates to novel compounds of formula (I) defined herein that are suitable for the non-enzymatic cleavage of target nucleic acids. The present invention also relates to the pharmaceutical compositions comprising the...
WO/2024/152536A1	S-(-)-6-METHYL NICOTINE SALICYLATE AND PREPARATION METHOD THEREFOR An S-6-methyl nicotine salicylate and a preparation method therefor. The preparation method comprises: firstly, preparing an (S)-6-methyl nicotine salicylate seed crystal; then dissolving (S)-6-methyl nicotine in an organic solvent to fo...
WO/2024/153175A1	HETEROAROMATIC COMPOUNDS AND THEIR USE AS USP1 INHIBITORS Provided herein are certain heteroaromatic compounds, such as a compound of Formula (I), as ubiquitin-specific-processing protease 1 (USP1) inhibitors, pharmaceutical compositions comprising the compounds, and method of use of the compou...
WO/2024/151833A1	SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF The present disclosure provides compounds of Formula I: (l) (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n,p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described...
WO/2024/151547A1	TARGETED DEGRADATION OF VAV1 This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human ...
WO/2024/149234A1	PARP7 INHIBITORS AND USES THEREOF PARP7 inhibitors and uses thereof are disclosed.
WO/2024/149261A1	INHIBITOR OF COMPLEMENT FACTOR B Provided in the present disclosure is an inhibitor of the complement factor B. The structure of the inhibitor of the complement factor B is substantially as represented by general formula (I), and the definition of each substituent in th...
WO/2024/148437A1	USE OF PCLX-001 OR PCLX-002 AS A RADIOSENSITIZER Described herein is the use of PCLX-001, PCLX-002 or pharmaceutically acceptable salts thereof as a radiosensitizer of cancerous cells in a subject in need of radiation therapy. The radio sensitizer is applied to a subject with cancer un...
WO/2024/092255A9	4-AMINOQUINOLINES FOR TREATMENT OF MULTIDRUG RESISTANT MALARIA The present invention concerns substituted N-(4-(piperidin-4-yl)phenyl)quinolin-4-amine and N-(4-(piperazin-l-yl)phenyl)quinolin-4-aminecompounds having the general Formula (I), below, and useful in the treatment of malaria, including Mu...
WO/2024/151346A1	HETEROARYL FLUOROALKENES AS DGK INHIBITORS The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
WO/2024/149676A1	HERBICIDAL PYRAZOLE COMPOUNDS The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein Q, R1, R2, R3 and m are as defined herein. The invention further relates to herbicidal compositions which comprise a...
WO/2024/151919A1	COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination and/or stereoisomers (e.g., enantiomers and diastereomers) of the compound) tha...
WO/2024/114663A9	CRYSTAL FORM OF TRIAZINYL METHYL CYCLOALKYL CARBOXYLIC ACID DERIVATIVE AND USE THEREOF The present application relates to a solvate solid form of a triazinyl methyl cycloalkyl carboxylic acid derivative as represented by formula (I), a crystal form thereof, a pharmaceutical composition comprising same, a preparation method...
WO/2024/149231A1	PARP7 INHIBITORS AND USES THEREOF Described herein, inter alia, are PARP7 inhibitors and uses thereof.
WO/2024/149675A1	HERBICIDAL IMIDAZOLE COMPOUNDS The present invention relates to compounds of Formula (I) or an agronomically acceptable salt of said compounds wherein Q, R1, R2, R3 and m are as defined herein. The invention further relates to herbicidal compositions which comprise a ...
WO/2024/149712A1	SELECTIVE ANGIOTENSIN II COMPOUNDS There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, in...
WO/2024/149728A1	SUBSTITUTED (HETERO)ANILINES AND THEIR USE The present disclosure relates to substituted anilines and heteroanilines and their use as TRPV4 antagonists. In some embodiments, the disclosure provides a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof, whe...
WO/2024/150815A1	CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR The problem addressed is to provide a novel compound having cereblon E3 ligase binding ability. Provided is a compound represented by formula (I): [in the formula, the symbols are as described in the specification.], formula (II): [in th...
WO/2024/149189A1	AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are an aromatic amide derivative, a preparation method therefor, and a use of a pharmaceutical composition containing the derivative in medicine. Specifically, provided are an aromatic amide derivative as represented by general ...
WO/2024/149360A1	BIQUATERNARY AMMONIUM SALT COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF A biquaternary ammonium salt compound and an pharmaceutical application thereof, specifically relating to a compound represented by general formula (I) or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically...
WO/2024/151809A1	INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME The present disclosure relates, in part, to compounds of Formula (I) and (II), which selectively inhibit Bone Morphogenetic Protein Receptor Type II (BMPR2), pharmaceutical compositions thereof, and methods of using the same for the trea...

Matches 1 - 50 out of 54,490	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >